The Role of Food Supplements in Insulin-Resistant Obesity Women with Polycystic Ovary Syndrome

doi:10.12280/gjfckx.20210729

Abstract

Abstract:

Polycystic ovary syndrome (PCOS) is a reproductive endocrine disease with highly incidence. Insulin resistance and obesity not only are the main clinical characteristics of PCOS, but also participate in the pathogenesis of PCOS. Food supplements such as inositol, docosahexaenoic acid, red yeast rice, berberine, curcumin, probiotic preparations and emerging functional foods may regulate glucose metabolism in PCOS through a variety of regulatory mechanisms and signal pathways, such as enhancing insulin sensitivity, regulating intestinal microflora, increasing anti-inflammatory and antioxidant activity, inhibiting liver gluconeogenesis and increasing glucose transport. The use of specific food supplements in obese patients with PCOS may improve symptoms and signs including insulin resistance and metabolism, promote ovulation and increase the pregnancy rate. In view of this, the narrative review is to discuss the mechanism of food supplements from the point of view of the relationship between obese women with PCOS and insulin resistance, so as to provide potential treatment for clinical treatment of PCOS.

Key words: Polycystic ovary syndrome, Insulin resistance, Food supplements, Obesity, Metabolism

SHI Bai-chao, WANG Yu, WU Xiao-ke. The Role of Food Supplements in Insulin-Resistant Obesity Women with Polycystic Ovary Syndrome[J]. Journal of International Obstetrics and Gynecology, 2022, 49(2): 166-171.

References 35

[1]	Aboeldalyl S, James C, Seyam E, et al. The Role of Chronic Inflammation in Polycystic Ovarian Syndrome-A Systematic Review and Meta-Analysis[J]. Int J Mol Sci, 2021, 22(5):2734. doi: 10.3390/ijms22052734. doi: 10.3390/ijms22052734
[2]	Trent M, Gordon CM. Diagnosis and Management of Polycystic Ovary Syndrome in Adolescents[J]. Pediatrics, 2020, 145(Suppl 2):S210-S218. doi: 10.1542/peds.2019-2056J. doi: 10.1542/peds.2019-2056J
[3]	Burt Solorzano CM, McCartney CR. Polycystic Ovary Syndrome: Ontogeny in Adolescence[J]. Endocrinol Metab Clin North Am, 2021, 50(1):25-42. doi: 10.1016/j.ecl.2020.10.003. doi: 10.1016/j.ecl.2020.10.003
[4]	McCartney CR, Campbell RE. Abnormal GnRH Pulsatility in Polycystic Ovary Syndrome: Recent Insights[J]. Curr Opin Endocr Metab Res, 2020, 12:78-84. doi: 10.1016/j.coemr.2020.04.005. doi: 10.1016/j.coemr.2020.04.005
[5]	Moghetti P, Tosi F. Insulin resistance and PCOS: chicken or egg?[J]. J Endocrinol Invest, 2021, 44(2):233-244. doi: 10.1007/s40618-020-01351-0. doi: 10.1007/s40618-020-01351-0
[6]	Vettorazzi A, López de Cerain A, Sanz-Serrano J, et al. European Regulatory Framework and Safety Assessment of Food-Related Bioactive Compounds[J]. Nutrients, 2020, 12(3):613. doi: 10.3390/nu12030613. doi: 10.3390/nu12030613
[7]	Gambioli R, Forte G, Aragona C, et al. The use of D-chiro-Inositol in clinical practice[J]. Eur Rev Med Pharmacol Sci, 2021, 25(1):438-446. doi: 10.26355/eurrev_202101_24412. doi: 10.26355/eurrev_202101_24412
[8]	Facchinetti F, Appetecchia M, Aragona C, et al. Experts′ opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond[J]. Expert Opin Drug Metab Toxicol, 2020, 16(3):255-274. doi: 10.1080/17425255.2020.1737675. doi: 10.1080/17425255.2020.1737675
[9]	Cabrera-Cruz H, Oróstica L, Plaza-Parrochia F, et al. The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment[J]. Am J Physiol Endocrinol Metab, 2020, 318(2):E237-E248. doi: 10.1152/ajpendo.00162.2019. doi: 10.1152/ajpendo.00162.2019
[10]	De Diego MV, Gómez-Pardo O, Groar JK, et al. Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: a preliminary study[J]. Arch Gynecol Obstet, 2020, 302(5):1169-1179. doi: 10.1007/s00404-020-05696-y. doi: 10.1007/s00404-020-05696-y
[11]	Zhang Y, Li C, Zhang W, et al. Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model[J]. J Med Food, 2020, 23(4):375-387. doi: 10.1089/jmf.2019.4580. doi: 10.1089/jmf.2019.4580
[12]	Lehner A, Staub K, Aldakak L, et al. Impact of omega-3 fatty acid DHA and EPA supplementation in pregnant or breast-feeding women on cognitive performance of children: systematic review and meta-analysis[J]. Nutr Rev, 2021, 79(5):585-598. doi: 10.1093/nutrit/nuaa060. doi: 10.1093/nutrit/nuaa060 pmid: 32918470
[13]	Abbott KA, Burrows TL, Acharya S, et al. DHA-enriched fish oil reduces insulin resistance in overweight and obese adults[J]. Prostaglandins Leukot Essent Fatty Acids, 2020, 159:102154. doi: 10.1016/j.plefa.2020.102154. doi: 10.1016/j.plefa.2020.102154
[14]	Amatruda M, Vizzuso S, Fabiano V, et al. Effect of Docosahexaenoic Acid Supplementation on Microbiota in Obese ChiLdrEn: A Pilot Study.(The DAMOCLE Study)[J]. Proceedings, 2020, 61:27. doi: 10.3390/IECN2020-07012. doi: 10.3390/IECN2020-07012
[15]	Magne F, Gotteland M, Gauthier L, et al. The Firmicutes/Bacteroidetes Ratio: A Relevant Marker of Gut Dysbiosis in Obese Patients?[J]. Nutrients, 2020, 12(5):1474. doi: 10.3390/nu12051474. doi: 10.3390/nu12051474
[16]	Fukami H, Higa Y, Hisano T, et al. A Review of Red Yeast Rice, a Traditional Fermented Food in Japan and East Asia: Its Characteristic Ingredients and Application in the Maintenance and Improvement of Health in Lipid Metabolism and the Circulatory System[J]. Molecules, 2021, 26(6):1619. doi: 10.3390/molecules26061619. doi: 10.3390/molecules26061619
[17]	Zhou W, Guo R, Guo W, et al. Monascus yellow, red and orange pigments from red yeast rice ameliorate lipid metabolic disorders and gut microbiota dysbiosis in Wistar rats fed on a high-fat diet[J]. Food Funct, 2019, 10(2):1073-1084. doi: 10.1039/c8fo02192a. doi: 10.1039/c8fo02192a
[18]	Hu J, Wang J, Gan QX, et al. Impact of Red Yeast Rice on Metabolic Diseases: A Review of Possible Mechanisms of Action[J]. J Agric Food Chem, 2020, 68(39):10441-10455. doi: 10.1021/acs.jafc.0c01893. doi: 10.1021/acs.jafc.0c01893
[19]	刘真, 殷冬梅, 战思恩, 等. 黄连素改善多囊卵巢综合征患者代谢异常的系统评价[J]. 首都医科大学学报, 2021, 42(4):588-595. doi: 10.3969/j.issn.1006-7795.2021.04.013. doi: 10.3969/j.issn.1006-7795.2021.04.013
[20]	王颖, 侯丽辉, 冯彦君, 等. 小檗碱对多囊卵巢综合征糖代谢的调节作用及机制研究进展[J]. 中华中医药杂志, 2020, 35(6):3019-3022.
[21]	Zhang SW, Zhou J, Gober HJ, et al. Effect and mechanism of berberine against polycystic ovary syndrome[J]. Biomed Pharmacother, 2021, 138:111468. doi: 10.1016/j.biopha.2021.111468. doi: 10.1016/j.biopha.2021.111468
[22]	褚玉超, 刘阳. 黄连素治疗2型糖尿病及其并发症作用机制研究进展[J]. 中医药临床杂志, 2019, 31(3):408-412. doi: 10.16448/j.cjtcm.2019.0120. doi: 10.16448/j.cjtcm.2019.0120
[23]	张跃辉, 赵微, 韩延华, 等. 黄连素对痰湿型多囊卵巢综合征大鼠的治疗作用及疗效机制研究[J]. 中华中医药学刊, 2019, 37(8):1807-1812. doi: 10.13193/j.issn.1673-7717.2019.08.003. doi: 10.13193/j.issn.1673-7717.2019.08.003
[24]	马健雄, 陈望强, 王晨晔, 等. 基于网络药理学探讨黄连对多囊卵巢综合征的作用机制[J]. 中药材, 2020, 43(9):2250-2257. doi: 10.13863/j.issn1001-4454.2020.09.034. doi: 10.13863/j.issn1001-4454.2020.09.034
[25]	Hodaei H, Adibian M, Nikpayam O, et al. The effect of curcumin supplementation on anthropometric indices, insulin resistance and oxidative stress in patients with type 2 diabetes: a randomized, double-blind clinical trial[J]. Diabetol Metab Syndr, 2019, 11:41. doi: 10.1186/s13098-019-0437-7. doi: 10.1186/s13098-019-0437-7 pmid: 31149032
[26]	Chien YJ, Chang CY, Wu MY, et al. Effects of Curcumin on Glycemic Control and Lipid Profile in Polycystic Ovary Syndrome: Systematic Review with Meta-Analysis and Trial Sequential Analysis[J]. Nutrients, 2021, 13(2):684. doi: 10.3390/nu13020684. doi: 10.3390/nu13020684
[27]	Heshmati J, Moini A, Sepidarkish M, et al. Effects of curcumin supplementation on blood glucose, insulin resistance and androgens in patients with polycystic ovary syndrome: A randomized double-blind placebo-controlled clinical trial[J]. Phytomedicine, 2021, 80:153395. doi: 10.1016/j.phymed.2020.153395. doi: 10.1016/j.phymed.2020.153395
[28]	吴锦林, 梅希, 唐偲, 等. 姜黄联合二甲双胍改善多囊卵巢综合征患者胰岛素抵抗的临床研究[J]. 中国中西医结合杂志, 2020, 40(4):406-412. doi: 10.7661/j.cjim.20191101.453. doi: 10.7661/j.cjim.20191101.453
[29]	Neyrinck AM, Rodriguez J, Zhang Z, et al. Prebiotic dietary fibre intervention improves fecal markers related to inflammation in obese patients: results from the Food4Gut randomized placebo-controlled trial[J]. Eur J Nutr, 2021, 60(6):3159-3170. doi: 10.1007/s00394-021-02484-5. doi: 10.1007/s00394-021-02484-5 pmid: 33544206
[30]	Suez J, Zmora N, Segal E, et al. The pros, cons, and many unknowns of probiotics[J]. Nat Med, 2019, 25(5):716-729. doi: 10.1038/s41591-019-0439-x. doi: 10.1038/s41591-019-0439-x
[31]	Vallianou N, Stratigou T, Christodoulatos GS, et al. Probiotics, Prebiotics, Synbiotics, Postbiotics, and Obesity: Current Evidence, Controversies, and Perspectives[J]. Curr Obes Rep, 2020, 9(3):179-192. doi: 10.1007/s13679-020-00379-w. doi: 10.1007/s13679-020-00379-w pmid: 32472285
[32]	张建秀, 柳慧哲, 朴光春, 等. 科罗索酸药理作用研究进展[J]. 国际药学研究杂志, 2019, 46(1):22-26. doi: 10.13220/j.cnki.jipr.2019.01.004. doi: 10.13220/j.cnki.jipr.2019.01.004
[33]	罗丹, 木泰华, 孙红男. 甘薯茎叶多酚分离纯化及降血糖活性研究进展[J]. 核农学报, 2021, 35(2):424-437.
[34]	高美玲, 余诚玮, 范亚苇, 等. 甘薯渣中可溶性膳食纤维对肠道菌群代谢产物的影响[J]. 中国食品学报, 2020, 20(12):56-61. doi: 10.16429/j.1009-7848.2020.12.008. doi: 10.16429/j.1009-7848.2020.12.008
[35]	Soleymani S, Habtemariam S, Rahimi R, et al. The what and who of dietary lignans in human health: Special focus on prooxidant and antioxidant effects[J]. Trends Food Sci Tech, 2020, 106(12):382-390. doi: 10.1016/j.tifs.2020.10.015. doi: 10.1016/j.tifs.2020.10.015